SUPN News and Press, Supernus Pharmaceuticals Inc. From 02/22/22

ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it received notice from the U.S. F...

In his book “Super Stocks” published nearly 40 years ago, Ken Fisher described an investing philosophy about high growth companies, trading at a discount. The philosophy combines elements of high growth and value, including both quantitative and qualitative factors. ...

Intercontinental Exchange will add 138 securities to the ICE Biotechnology index and delete 26 as part of the annual reconstitution, effective prior to market open on December 20. Notable additions: Aurinia Pharmaceuticals (NASDAQ:AUPH), Anavex Life Sciences (NASDAQ:AVXL), Sesen Bio...

ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Applica...

Jefferies has reinstated the coverage of Supernus Pharmaceuticals (SUPN +6.9%) with a Buy rating on the completion of the company’s $850M acquisition of Adamas Pharmaceuticals in November. With the closure of the deal, the analysts led by David Steinberg project the acquisition to...

Initially a VOIP service provider, Vonage refocused its business from a home phone provider to a global business cloud communications provider. This transformation was key to Vonage's recent success. Ericsson to acquire Vonage for $6.2 billion or $21 per share in cash, representin...

The attack had no significant impact on the business and did not cause any significant disruption to Company’s operations No ransom payments have been made by the Company ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDA...

ROCKVILLE, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company’s management wi...

Image source: The Motley Fool. Supernus Pharmaceuticals, inc (NASDAQ: SUPN) Q3 2021 Earnings Call Nov 3, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Supernus Pharmaceuticals, inc (SUPN) Q3 2021 Earnings Call Tra...

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2021 Earnings Conference Call November 03, 2021 04:30 PM ET Company Participants Peter Vozzo - Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants David Steinberg - Jefferi...